5-Hydroxy-PGI1 compounds

ABSTRACT

This invention relates to certain structural analogs of 5,6-dihydroprostacyclin (PGI 1 ) wherein the C-5 carbon atom is substituted by hydroxy. These novel 5-hydroxyprostacyclin-type compounds are smooth muscle stimulators.

The present application is a continuation-in-part of Ser. No. 815,648, filed July 14, 1977, issued as U.S. Pat. No. 4,110,532 on Aug. 29, 1978.

The essential material constituting a disclosure for the preparation and use of the present invention is incorporated here by reference from U.S. Pat. No. 4,110,532.

BACKGROUND OF THE INVENTION

This invention relates to novel structural analogs of 5,6-dihydroprostacyclin (PGI₁). In particular, the present invention relates to prostacyclin-type compounds wherein the C-5 carbon atom of 5,6-dihydroprostacyclin is substituted by a hydroxy.

SUMMARY OF THE INVENTION

The present invention particularly comprises:

A prostacyclin analog of the formula ##STR1## wherein R₇ is (1) --(CH₂)_(m) --CH₃, ##STR2## wherein m is the integer one to 5, inclusive, h is the integer zero to 3, inclusive; s is the integer zero, one, 2 or 3, and T is chloro, fluoro, trifluoromethyl, alkyl of one to 3 carbon atoms, inclusive, or with the proviso that not more than two T's are other than alkyl;

wherein Z₂ is ##STR3## wherein one of p or q is the integer zero or one and the other is the integer zero;

wherein Z₁ is

(1) --(CH₂)_(g) --CH₂ --CH₂ --,

(2) --(CH₂)_(g) --CH₂ --CF₂ --, or

(3) trans--(CH₂)_(g) --CH═CH--,

wherein g is the integer one, 2, or 3 when q is zero and zero, one, or 2 when q is one;

wherein R₈ is hydrogen, hydroxy, or hydroxymethyl;

wherein Y₁ is

(1) trans--CH═CH--,

(2) cis--CH═CH--,

(3) --CH₂ CH₂ --,

(4) trans--CH═C(Hal)--, or

(5) --C.tbd.C--

wherein Hal is chloro or bromo;

wherein M₁ is ##STR4## wherein R₅ is hydrogen or alkyl with one to 4 carbon atoms, inclusive;

wherein L₁ is ##STR5## a mixture of ##STR6## wherein R₃ and R₄ are hydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R₃ and R₄ is fluoro only when the other is hydrogen or fluoro;

wherein X₁ is

(1) --COOR₁ ; wherein R₁ is hydrogen, alkyl of one to 12 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, phenyl substituted with one, two, or three chloro or alkyl of one to 3 carbon atoms, inclusive, or a pharmacologically acceptable cation,

(2) --CH₂ OH,

(3) --CH₂ NL₂ L₃, wherein L₂ and L₃ are hydrogen, alkyl of one to 4 carbon atoms, inclusive, or --COOR₁, wherein R₁ is as defined above;

(4) --COL₄, wherein L₄ is

(a) amino of the formula --NR₂₁ R₂₂, wherein R₂₁ and R₂₂ are hydrogen, alkyl of one to 12 carbon atoms, inclusive; aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, phenyl substituted with one, 2, or 3 chloro or alkyl of one to 3 carbon atoms, inclusive, or phenyl substituted with hydroxycarbonyl or alkoxycarbonyl of one to 4 carbon atoms, inclusive;

(b) cycloamino selected from the group consisting of ##STR7## wherein R₂₁ and R₂₂ are as defined above; (c) carbonylamino of the formula --NR₂₃ COR₂₁,

wherein R₂₃ is hydrogen or alkyl of one to 4 carbon atoms and R₂₁ is as defined above;

(d) sulphonylamino of the formula --NR₂₃ SO₂ R₂₁, wherein R₂₁ and R₂₃ are as defined above; or

(5) --COOL₅, wherein L₅ is p-substituted phenyl selected from the group consisting of ##STR8## wherein R₂₄ is methyl, phenyl, acetamidophenyl, benzamidophenyl, or --NH₂ ; R₂₅ is methyl, phenyl, --NH₂, or methoxy; and R₂₆ is hydrogen or acetamido; and the 1,5- and 1,15-lactones thereof. 

We claim:
 1. A prostacyclin analog of the formula ##STR9## wherein R₇ is (1) --(CH₂)_(m) --CH₃, ##STR10## wherein m is the integer one, 2, 4, or 5; h is the integer 2 or 3; s is the integer zero, one, 2, or 3, and T is chloro, fluoro, trifluoromethyl, alkyl of one to 3 carbon atoms, inclusive, or with the proviso that not more than two T's are other than alkyl;wherein Z₂ is ##STR11## wherein Z₁ is (1) --(CH₂)_(g) --CH₂ --CH₂ --, (2) --(CH₂)_(g) --CH₂ --CF₂ --, or (3) trans--(CH₂)_(q) --CH═CH--, wherein R₈ is hydrogen, hydroxy, or hydroxymethyl; wherein Y₁ is (1) trans--CH═CH--, (2) cis--CH═CH--, (3) --CH₂ CH₂ --, (4) trans--CH═C(Hal)--, or (5) --C.tbd.C--wherein Hal is chloro or bromo; wherein M₁ is ##STR12## wherein R₅ is hydrogen or alkyl with one to 4 carbon atoms, inclusive; wherein L₁ is ##STR13## a mixture of ##STR14## wherein R₃ and R₄ are hydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R₃ and R₄ is fluoro only when the other is hydrogen or fluoro; wherein X₆ is (1) --COOR₁ ; wherein R₁ is hydrogen, alkyl of one to 12 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, phenyl substituted with one, two, or three chloro or alkyl of one to 3 carbon atoms, inclusive, or a pharmacologically acceptable cation, (2) --CH₂ OH, (3) --CH₂ NL₂ L₃, wherein L₂ and L₃ are hydrogen, alkyl of one to 4 carbon atoms, inclusive, or --COOR₁, wherein R₁ is as defined above; (4) --COL₄, wherein L₄ is(a) amino of the formula --NR₂₁ R₂₂, wherein R₂₁ and R₂₂ are hydrogen, alkyl of one to 12 carbon atoms, inclusive; aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, phenyl substituted with one, 2, or 3 chloro or alkyl of one to 3 carbon atoms, inclusive, or phenyl substituted with hydroxycarbonyl or alkoxycarbonyl of one to 4 carbon atoms, inclusive; (b) carbonylamino of the formula --NR₂₃ COR₂₁, wherein R₂₃ is hydrogen or alkyl of one to 4 carbon atoms and R₂₁ is as defined above; or (c) sulphonylamino of the formula --NR₂₃ SO₂ R₂₁, wherein R₂₁ and R₂₃ are as defined above; or (5) --COOL₅, wherein L₅ is p-substituted phenyl selected from the group consisting of ##STR15## wherein R₂₄ is methyl, phenyl, acetamidophenyl, benzamidophenyl, or --NH₂ ; R₂₅ is methyl, phenyl, --NH₂, or methoxy; and R₂₆ is hydrogen or acetamido, and the 1,5- and 1,15-lactones thereof. 